Welcome to the Entresto on-demand webinars page. Below you can access recordings from educational webinars that were hosted by experts in the field of heart failure and were organised by Novartis.
You will be required to register to watch the videos.
Early initiation of Entresto® (sacubitril/valsartan): alter the cycle of readmission in patients with heart failure
Watch Dr Aaron Wong and Professor Jawad Khan present how early initiation of Entresto can alter the cycle of readmission in chronic HFrEF patients, looking at local data supporting this. This webinar was recorded at the 2020 Heart Rhythm Congress which took place online on 27-30th September 2020.
Treating the newly diagnosed chronic HFrEF patient – what should you prescribe?
In this Novartis sponsored webinar from 14th July 2021, Dr Patricia Campbell, Dr Katherine McCreary and Mandie Welch discuss the supporting evidence and real-world experience in initiating Entresto within this patient population.
The impact of disease-modifying treatment: A patient’s perspective
A recording from the Novartis symposium at the 24th annual British Society for Heart Failure meeting, which took place virtually in December 2021.
After talking to a patient about his heart failure diagnosis and treatment, cardiologist Dr Patricia Campbell explores optimal treatment for chronic HFrEF and its impact on patient outcomes.
10th BSH Heart Failure Nurse and Allied Healthcare Professional Education Day webinar
Watch the Novartis virtual Meet the Expert and Symposium sessions from the 10th BSH Heart Failure Nurse and Allied Healthcare Professional Education Day on 21st May 2021.
25th Annual BSH Meeting
Join Dr Parminder Chaggar and Dr Geraint Jenkins as they discuss the latest guidelines on HFrEF management in the symposium sessions from the 25th BSH meeting in December 2022. Watch as they explore ways to optimise treatment in chronic HFrEF patients, focusing on management in those who are newly diagnosed.
PCCS symposium 2022: The role of primary care in HF management – an integrated care system approach
Watch the Novartis symposium held at the PCCS Annual Conference which took place virtually in September 2022.
In this webinar Rocco Hadland and Dr Rajiv Sankaranarayanan share local experience, and advise on how primary care can actively identify and manage HF patients whilst collaborating with other services to reduce admissions.
Indication: Entresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.1
BSH, British Society for Heart Failure; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; PCCS, Primary Care Cardiovascular Society.
Reference
- Entresto Summary of Product Characteristics, 2021.